Faeth Therapeutics, Inc. FTH
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +87.35%
- 1 year
- +130.30%
- Market cap
- 516.62M
- EPS (ttm)
- -60.86
- Shares out
- 25.84M
- Forward P/E
- -7.88
- YTD return
- +87.35%
- 1-year return
- +130.30%
- Volume
- 236.01K
- Avg volume
- 366.51K
- Open
- 20.34
- Previous close
- 19.65
- Day's range
- 19.08 – 20.44
- 52-week range
- 7.45 – 42.14
- Beta
- -0.28
- Analysts
- Strong Buy
- Price target
- 54.64 (+173.3%)
- Earnings date
- Nov 13, 2026
2Y +9.17 (+88.34%)
Key statistics
- Enterprise value
- 781.62M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 855.13K
- Total cash
- 186.44M
- Total debt
- 592.00K
- Return on equity
- -195.26%
- Short % of float
- 4.32%
- 50-day average
- 30.99
- 200-day average
- 22.28
Analyst view
Consensus: strong buy
- Target (low)
- 46.00
- Target (mean)
- 54.64
- Target (high)
- 60.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 13, 2026
Expected Nov 13, 2026. Consensus EPS estimate -0.66.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -0.66 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -2.64 | -2.84 | -0.20 | -7.58% |
| May 15, 2026 | Mar 31, 2026 | -0.62 | -131.45 | -130.83 | -21,101.61% |
| Mar 30, 2026 | Dec 31, 2025 | -4.81 | -3.74 | +1.07 | +22.25% |
| Nov 14, 2025 | Sep 30, 2025 | -4.11 | -3.62 | +0.49 | +11.92% |
| Aug 5, 2025 | Jun 30, 2025 | -6.20 | -3.91 | +2.29 | +36.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 2026 | LUCID CAPITAL MARKETS | init | — | Buy |
| Sep 9, 2026 | TD Cowen | init | — | Buy |
| Aug 21, 2026 | Needham | init | — | Buy |
| Aug 11, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 4, 2026 | Jones Trading | init | — | Buy |
| Jul 31, 2026 | Raymond James | init | — | Outperform |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- faeththerapeutics.com
News
Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 
Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate 
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates 
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors - BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib 
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026 
Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Up – Here’s What Happened 
William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating
Your note
Sign in to keep a note on FTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | Sale | May 31, 2026 | 130,142 |
| HAHN STEPHEN M | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 44,763 |
| MILLENNIUM MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 6, 2026 | 0 |
| PARIKH ANAND KIRAN J.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 21, 2026 | 817,699 |
| PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | Sale | May 31, 2026 | 130,142 |
| STEPHENSON BRIAN C | Chief Financial Officer | Purchase | Jun 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 7.82% | 2,020,103 | 78.97M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.59% | 1,444,039 | 56.45M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 4.98% | 1,286,411 | 50.29M | Jun 29, 2026 |
| Balyasny Asset Management LP | 4.03% | 1,042,198 | 40.74M | Jun 29, 2026 |
| Cormorant Asset Management, LP | 3.98% | 1,028,242 | 40.19M | Jun 29, 2026 |
| RA Capital Management, L.P. | 2.79% | 722,020 | 28.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.19% | 48,771 | 1.91M | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 15,907 | 621.80K | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.04% | 10,115 | 395.39K | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.02% | 4,560 | 178.25K | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 0.01% | 1,360 | 53.16K | Apr 29, 2026 |
| iShares Trust-iShares Micro-Cap ETF | 0.01% | 3,192 | 124.78K | Jun 29, 2026 |